

Complete genome sequence of the bacteriophage YMC/09/04/R1988 MRSA BP: a lytic phage from a methicillin-resistant *Staphylococcus aureus* isolate

Jongsoo Jeon, Roshan D'Souza, Sung Kuk Hong, Yangsoon Lee, Dongeun Yong, Jongrak Choi, Kyungwon Lee & Yunsop Chong

Department of Laboratory Medicine and Research Institute of Antimicrobial Resistance, Yonsei University College of Medicine, Seoul, Korea

Correspondence: Dongeun Yong,
Department of Laboratory Medicine and
Research Institute of Bacterial Resistance,
Yonsei University College of Medicine, 50
Yonsei-ro, Seodaemun-gu, Seoul 120-752,
Korea. Tel.: +82 2 2228 2446;
fax: +82 2 364 1583;
e-mail: deyong@yuhs.ac

Received 14 July 2014; accepted 12 August
2014. Final version published online
4 September 2014.

DOI: 10.1111/1574-6968.12580

Editor: Mark Enright

Keywords

antibiotic resistant bacteria; lytic
bacteriophage; alternative therapeutic agent;
infection.

Bacteriophages (phages) are specific bacterial viruses that infect and lyse host bacteria. As bacteriophages were discovered and isolated by Felix d'Herelle in the early 20th century, a number of treatments for bacterial infections using bacteriophage therapy have been reported (Wittebole *et al.*, 2014). Bacteriophage therapy was restrictively researched and applied because of the discovery and development of antibiotics. Recently, however, the rise and emergence of multiantibiotic-resistant bacteria has led to an increasing interest in phages as new therapeutic agents (Merril *et al.*, 2003).

Staphylococcus aureus, a Gram-positive bacterium, is one of the most important pathogens causing several serious infections (Styers *et al.*, 2006). In particular, since methicillin-resistant *Staphylococcus aureus* (MRSA) was first reported in the 1960s, infections with MRSA have been rising globally and are difficult to treat due to acquired resistance to most commonly antimicrobial agents (Grundmann *et al.*, 2006). As a result, bacteriophages such as *S. aureus* phage ϕ 812, ϕ MR11, and S13

Abstract

Methicillin-resistant *Staphylococcus aureus* (MRSA) is an increasing cause of serious infection, both in the community and hospital settings. Despite sophisticated strategies and efforts, the antibiotic options for treating MRSA infection have been narrowed due to the limited number of newly developed antimicrobials. Herein, we analyze the completely sequenced genome of a novel virulent phage YMC/09/04/R1988 MRSA BP as a potential alternative anti-MRSA agent, which lysed clinical isolates from a patient admitted to the hospital due to hip disarticulation. The phage contains a linear double-stranded DNA genome of 44,459 bp in length, with 33.37% GC content, 62 predicted open reading frames (ORFs), and annotated functions of only 23 ORFs that are associated with structural assembly, host lysis, DNA replication, and modification. It showed a broad host range (17 of 30 strains) against MRSA strains in clinical isolates.

have been newly studied as alternative therapeutic tools to combat pathogens (Pantucek *et al.*, 1998; Matsuzaki *et al.*, 2003; Rahman *et al.*, 2011; Deghorain & Van Melderen, 2012; Takemura-Uchiyama *et al.*, 2014).

In this study, we isolated and characterized a novel lytic bacteriophage, B ϕ -R1988 (YMC/09/04/R1988 MRSA BP), which lyses MRSA strains. To our knowledge, this is the first study of a bacteriophage active against MRSA strains isolated from a hospital patient in Korea, and this bacteriophage has application as a new antibiotic agent.

B ϕ -R1988 was isolated from a sewage sample and purified by the agar double-layer method (Kropinski *et al.*, 2009). A spot test (Kropinski *et al.*, 2009) was used to determine the host range of the B ϕ -R1988. MRSA strains were collected from clinical isolates from a university hospital in South Korea and were used to isolate bacteriophages. The genomic DNA was prepared by the phenol extraction method (Wilcox *et al.*, 1996) and was sequenced using the Illumine Genome Analyzer (272-fold average coverage; Illumina, Inc., San Diego, CA).




Fig. 1. Genome comparison of B ϕ -R1988 and *Staphylococcus* phage phi12, phage phi2958PVL, and phage phi310-1 at the DNA level. This analysis was carried out using MAUVE software 2.3.1 with default parameters. Connection lines indicate similar regions between ORFs of B ϕ -R1988 and three *Staphylococcus* phages. White blocks indicate annotated genes and reverse strands shifted downward (a). The genome map of B ϕ -R1988 indicates a putative function of each ORF with the direction of transcription shown by arrows (b).

The novel MRSA virulent phage, B ϕ -R1988, contained double-stranded DNA with 44,459 bp and a G + C content of 33.37%. Genome analysis of the phage revealed 62 putative open reading frames (ORFs), and tRNA genes were not identified; however, most of the annotated genes (40 of 62 ORFs) were hypothetical proteins (Table S1, Supporting information). According to the morphological characteristics by transmission electronic microscopy (JEOL JEM-1011, Tokyo, Japan), B ϕ -R1988 has a prolate icosahedral head and a long noncontractile tail, and thus, it belongs to the family *Siphoviridae* in the order *Caudovirales*.

Genome alignment was performed using MAUVE software (Darling *et al.*, 2004), and phage B ϕ -R1988 was compared with three other phages (Fig. 1a). The results showed relatively high extensive homology that was located between 20 and 24,049 bp (DNA packaging, structural protein, and lysis regions) and 24,236–44,374 bp (DNA replication, and modification regions) in the B ϕ -R1988 DNA region and between 21,118–44,406 bp and 979–20,694 bp in the phi2958PVL DNA region, respectively. As mentioned above, most of the genome of phage B ϕ -R1988 was arranged in the reverse

direction with phage phi2958PVL, phage phi12, and phage tp310-2. However, some ORFs associated with each functional DNA cluster in the genome showed a different direction. B ϕ -R1988 showed 86% similarity to phage phi2958PVL at the DNA level, having a genome size of 47,342 bp (GenBank accession no. AP009363, unclassified phage) and indicated 89% DNA sequence similarities to phage phi 12 (GenBank Accession No. AF424782) and phage tp310-2 (GenBank Accession No. EF462198) belonging to *Siphoviridae*, which have genome sizes of 44,970 and 47,785 bp, respectively (Fig. 1a).

The genome of B ϕ -R1988 is comprised of the following three functional protein clusters: (1) DNA packaging and structural assembly proteins (ORF1, ORF2: small and large subunits of terminase, ORF3: portal protein, ORF5: major head protein, ORF6: DNA packaging protein, ORF10: tail protein, ORF14, ORF15: tail length tape measure protein), (2) host lysis proteins (ORF24: holin, ORF25: endolysin), and (3) DNA replication and modification proteins (ORF27: phage integrase, ORF33: regulatory protein, ORF40: Transcriptional regulator, ORF44: DNA-directed DNA polymerase, ORF61: translational regulator, ORF62: endonuclease; Fig. 1b).

Endolysins are phage-encoded enzymes that lyse target bacteria by specifically destroying them through peptidoglycan digestion (Loessner, 2005). In addition, the holin is a phage-encoded small-membrane protein that forms holes in the cytoplasmic membrane, which allows the endolysin to escape and break the peptidoglycan (Wang *et al.*, 2000).

As ORF24 and ORF25 are lysis modules, ORF24 identified as a holin-exhibited 100% protein sequence identity to the *Staphylococcus* phage phiSLT (GenBank Accession No. NP_075521.1). The ORF25 identified as a putative *N*-acetylmuramoyl-L-alanine amidase possessing lysis activity of host peptidoglycan showed high protein sequence identity (98%) to sequences from *Staphylococcus* phage tp310-1 (GenBank Accession No. YP_001429893.1). Furthermore, the sequences of ORF5 (phage head protein) and ORF10 (phage tail protein) are highly similar to those of phage phiSLT, both with 100% homology.

In addition, B ϕ -R1988 exhibited a broad lytic spectrum (17 of 30 strains) through host range studies against collected MRSA strains of hospital patients, which were typed using pulsed-field gel electrophoresis (PFGE; data not shown).

In this study, a novel lytic bacteriophage, B ϕ -R1988, which lyses MRSA strains, was isolated and sequenced. This is the first report about a lytic bacteriophage against clinical MRSA strains collected from patients at a hospital in South Korea.

GenBank database Accession Number: KF598856.

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2012R1A1A2009064) and by a grant from the Brain Korea 21 PLUS Project for Medical Science, Yonsei University. We are grateful to Ms. Sori Jong for technical assistance.

References

- Darling AC, Mau B, Blattner FR & Perna NT (2004) MAUVE: multiple alignment of conserved genomic sequence with rearrangements. *Genome Res* **14**: 1394–1403.
- Deghorain M & Van Melderen L (2012) The *Staphylococci* phages family: an overview. *Viruses* **4**: 3316–3335.
- Grundmann H, Aires-de-Sousa M, Boyce J & Tiemersma E (2006) Emergence and resurgence of methicillin-resistant *Staphylococcus aureus* as a public-health threat. *Lancet* **368**: 874–885.
- Kropinski AM, Mazzocco A, Waddell TE, Lingohr E & Johnson RP (2009) Enumeration of bacteriophages by double agar overlay plaque assay. *Methods Mol Biol* **501**: 69–76.
- Loessner MJ (2005) Bacteriophage endolysins—current state of research and applications. *Curr Opin Microbiol* **8**: 480–487.
- Matsuzaki S, Yasuda M, Nishikawa H *et al.* (2003) Experimental protection of mice against lethal *Staphylococcus aureus* infection by novel bacteriophage phi MR11. *J Infect Dis* **187**: 613–624.
- Merrill CR, Scholl D & Adhya SL (2003) The prospect for bacteriophage therapy in Western medicine. *Nat Rev Drug Discov* **2**: 489–497.
- Pantucek R, Rosypalova A, Doskar J *et al.* (1998) The polyvalent staphylococcal phage phi 812: its host-range mutants and related phages. *Virology* **246**: 241–252.
- Rahman M, Kim S, Kim SM, Seol SY & Kim J (2011) Characterization of induced *Staphylococcus aureus* bacteriophage SAP-26 and its anti-biofilm activity with rifampicin. *Biofouling* **27**: 1087–1093.
- Styers D, Sheehan DJ, Hogan P & Sahn DF (2006) Laboratory-based surveillance of current antimicrobial resistance patterns and trends among *Staphylococcus aureus*: 2005 status in the United States. *Ann Clin Microbiol Antimicrob* **5**: 2.
- Takemura-Uchiyama I, Uchiyama J, Osanai M *et al.* (2014) Experimental phage therapy against lethal lung-derived septicemia caused by *Staphylococcus aureus* in mice. *Microbes Infect* **16**: 512–517.
- Wang IN, Smith DL & Young R (2000) Holins: the protein clocks of bacteriophage infections. *Annu Rev Microbiol* **54**: 799–825.
- Wilcox SA, Toder R & Foster JW (1996) Rapid isolation of recombinant lambda phage DNA for use in fluorescence *in situ* hybridization. *Chromosome Res* **4**: 397–398.
- Wittebole X, De Roock S & Opal SM (2014) A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. *Virulence* **5**: 226–235.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Data S1. Material and methods.

Table S1. Features of annotated putative ORFs in YMC/09/04/R1988 MRSA BP.